REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
== Personnel == Russ Gershon – tenor saxophone, soprano saxophone, flute, arranger John Carlson, Tom Halter – trumpet, flugelhorn Curtis Hasselbring, Russell Jewell – trombone Douglas Yates – alto saxophone, soprano saxophone Charlie Kohlhase – alto saxophone, baritone saxophone John Medeski – piano, organ, DX7 John Dirac – electric guitar, arranger Mike Rivard – bass Jerome Deupree – drums Mark Sandman – vocals, guitar, arranger (track 5) Robb Rawlings – alto saxophone (track 5) Dave Finucane – bass clarinet (track 5) Kenny Freundlich – piano, synthesizer (track 5)
Enzyme-linked receptors (or catalytic receptors) are transmembrane receptors that, upon activation by an extracellular ligand, causes enzymatic activity on the intracellular side. Hence a catalytic receptor is an integral membrane protein possessing both enzymatic, catalytic, and receptor functions. They have two important domains, an extra-cellular ligand binding domain and an intracellular domain, which has a catalytic function; and a single transmembrane helix. The signaling molecule binds to the receptor on the outside of the cell and causes a conformational change on the catalytic function located on the receptor inside the cell. Examples of the enzymatic activity include:
The group released one album in 1965 and three albums in 1966. Dino, Desi & Billy albums contained primarily versions of Top 40 songs made popular by others, with new content being minor. The three boys made an appearance in the Dean Martin film Murderers' Row and sang the Boyce & Hart song, "If You're Thinkin' What I'm Thinkin'". From 1966 to 1970, the group continued to release singles, encountering marginal success, which was not altered by a change of label to Columbia Records in 1969. Also in 1969, the group contributed three songs to the soundtrack of the surf film Follow Me. The group received top billing on the soundtrack album, despite the fact that most of the album featured music by composer Stu Phillips. Later in 1969 the group broke up, due in part to Desi joining his mother's television show and Hinsche wishing to commence university studies. The group was never a favorite of the critics. Writing for AllMusic, music critic Richie Unterberger characterized them as a group that "never had an ounce of credibility", with music that was "innocuously bland in the extreme." These sentiments may be contrasted with the fact that the band was well thought of by the Beach Boys, to the extent that Brian Wilson and Hinsche co-wrote one of the band's original songs, and their final single, "Lady Love". That single was released by Reprise Records in 1970, after the group had broken up. Hinsche's sister, Annie, married Carl Wilson and Hinsche himself worked with the Beach Boys as a backing musician for many years.
Sources: en.wikipedia.org
3 spot in Entrepreneur magazine's 31st Annual Franchise 500, "the first and most comprehensive ranking in the world". This was the 17th year 7-Eleven was named in the top 10. In February 2010, 7-Eleven opened a concept store in DeLand, Florida, across from Stetson University, designed to meet LEED environmental standards. In 2017 they bought 1,110 C-Stores convenience stores from Sunoco in a deal valued at $3.3 billion and in 2024 acquired 204 Stripes convenience stores from Sunoco in a deal valued at $1 billion and finished integrating them in 2026. By 2015, 7-Eleven had over 55,000 stores across the world. In 2020, 7-Eleven announced it would purchase Speedway, 23,000 stores, for $21 billion. In 2021, 7-Eleven rolled out a $70 million ad campaign, their largest investment in advertising in years, doubling their market spending from the previous year. The commercials, directed by Harmony Korine, were to reflect the "evolution" of the chain's store format, drawing attention to, in part, the fact that "this isn't just gas station food, there's real restaurant quality food at 7-Eleven", according to CMO Marissa Jarrantt. On August 19, 2024, it was reported that Alimentation Couche-Tard—owner of competitor Circle K—had made a buyout offer for Seven & i Holdings. Later, on September 6, 2024, Seven & i Holdings rejected this offer as too low and rife with regulatory risk, although a "sweetened offer" might be considered. In October, a revised bid of $47 billion, 22% increase of the previous one, was presented.
== External links == Guidance for the Care of Human Remains in Museums, published by the Department for Culture, Media and Sport (England, Wales, and Northern Ireland) Introduction to human remains in museums, published by Museum Galleries Scotland Recommendations for the Care of Human Remains in Museums and Collections, published by Deutscher Museumsbund (German Museums Association) Full Wellcome Trust policy on the care of human remains in museums and galleries
Blood pressure ≥140/90 mmHg Dyslipidemia: TG ≥1.695 mmol/L and HDL-C ≤0.9 mmol/L (men), ≤1.0 mmol/L (women) Central obesity: waist:hip ratio >0.90 (men); >0.85 (women), or BMI >30 kg/m2 Microalbuminuria: urinary albumin excretion ≥20 μg/min or albumin:creatinine ≥30 mg/g
== Catalyzed reaction == Tyrosinase carries out the oxidation of phenols such as tyrosine and dopamine using molecular oxygen (O2). In the presence of catechol, benzoquinone is formed (see reaction below). Hydrogens removed from catechol combine with oxygen to form water. The substrate specificity becomes dramatically restricted in mammalian tyrosinase which uses only L-form of tyrosine or DOPA as substrates, and has restricted requirement for L-DOPA as cofactor.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.